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Mouseansferase 1 (GPAT1) is a rate limiting enzyme in de novo glycerophospholipid
synthesis. The murine GPAT1 promoter sequence (the “classical” sequence) was reported previously. However,
the organization of this DNA sequence does not fully match the mouse genome sequences on NCBI/GenBank.
Here we have identiﬁed net cis-acting promoter sequences for the mouse GPAT1 gene: promoter 1a which
includes part of the classical sequence and the downstreampromoter 1b. Promoter 1a facilitates transcription of
two alternative GPAT1 transcript variants, GPAT1-V1 and V2, while promoter 1b produces a third transcript
variant, GPAT1-V3. Upstream stimulating factor-1 (USF-1) controlled both promoters whereas sterol regulatory
element-binding protein-1 (SREBP-1) exclusively regulated promoter 1a activity in vitro. Feeding increased
GPAT1-V1 and V2, but not V3 mRNA levels in mouse liver. The obese condition of db/db mice did not alter the
hepatic expression levels of any of the three GPAT1 variants. Feeding enhanced hepatic mRNA levels,
intranuclear protein levels and promoter 1a-binding levels of SREBP-1, but not of USF-1. Thus, promoter 1awas
exclusively activated by routine feeding in vivo. Our results indicate differential roles of the two promoters in the
regulation of hepatic GPAT1 gene expression in mice.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionGlycerol-3-phosphate acyltransferase (GPAT) acts as a rate limiting
enzyme in de novo synthesis of triacylglycerol (TAG) and phospholipids
[1,2]. GPATcatalyzes the ﬁrst step in glycerophospholipid synthesis, i.e.,
it acts at the esteriﬁcation of glycerol-3-phosphate in the sn-1 position
with a fatty acyl-CoA to form 1-acylglycerol-3-phosphate (lysophos-
phatidic acid) [1,2]. Four GPAT isoforms, GPAT1 [3], xGPAT1/GPAT2
[4,5], GPAT3/AGPAT8 [6] and GPAT4/AGPAT6 [7,8], have been identiﬁedansferase 1; USF-1, upstream
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l rights reserved.in mammals. GPAT1 is localized in the outer mitochondrial membrane
and its enzymatic activity can be distinguished from the other three
GPAT isoforms by its differential sensitivity to sulfhydryl reagents such
as N-ethylmaleimide [2,7]. GPAT1 transcript is ubiquitously expressed
inmammalian tissues [9]. However, inmost tissues, GPAT1 accounts for
less than 10% of total GPATactivity, while in the liver its activity is about
50%of the total [2,10], suggesting a signiﬁcant role ofGPAT1 in liver lipid
metabolism.
In rat hepatocytes, exogenous overexpression of GPAT1 results in
increased synthesis of diacylglycerol andTAG from fatty acids [11]. Such
accumulation of TAG by GPAT1 overexpression has also been demon-
strated in non-hepatic cells, including Chinese hamster ovary cells [12].
Experimental studies in laboratory animals also have demonstrated
that adenoviral overexpression of GPAT1 in the liver results in hepatic
steatosis with high accumulation and secretion of TAG [13], whereas a
gene knockout or an RNA-interference (RNAi)-induced knockdown of
this gene results in a reduction of TAG levels in the liver [14,15]. In
addition, a recent study has clearly shown in rats that overexpression of
GPAT1 in the liver induces hepatic and systemic insulin resistance [16].
Thus, we believe that GPAT1 is a good candidate for targeted treatment
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type 2 diabetes with insulin resistance [17].
The cDNA of GPAT1 was cloned ﬁrst in mouse [3], which was
followed by cloning in rat [18] and human [17]. Hepatic expression of
GPAT1 mRNA has been reported to be decreased by fasting while it is
increased by feeding or insulin treatment in vivo [3]. Obese mice with
hyperphagia showed high levels of GPAT activity and protein levels in
the liver [11], although it is not clear whether the mRNA levels of
GPAT1 speciﬁcally were changed in this study.
The mouse GPAT1 gene is located on Chromosome 19 [19]. In 1995,
Jerkins et al. reported a promoter sequence for the mouse GPAT1 gene
[20]. The authors also demonstrated using 3T3-L1 adipocytes that the
promoter region encoding nucleotides −322 bp (corrected as −325 bp in
this paper) to +102 (relative to the transcription start site) would
contain a responsive sequence to insulin or a high glucose environment
[20]. Subsequently, Ericsson et al. [21] found three functional sterol
regulatoryelements (SREs) in this region anddemonstrateda signiﬁcant
upregulation of the promoter's activity by SRE-binding protein-1
(SREBP-1), a critical transcription factor for the transcriptional control
of lipogenic genes [22]. An additional study by Grifﬁn et al. has also
suggested that bindingof anupstream stimulating factor 1 (USF-1) to an
E-box-like sequence (CATGTG) in this proximal promoter region plays a
role in GPAT1 expression [23]. Thus, this proximal region (325 bp) of the
GPAT1 promoter has been implicated in both the nutritional as well as
hormonal induction of the GPAT1 gene in the liver [20,23].
The murine GPAT1 promoter sequence (with a putative exon 1
sequence) that was reported previously (the classical sequence) [20] is
registered inNCBI/GenBankunderaccessionnumberU11680.However,
our in silico analysis that was based on the information from NCBI/
GenBank has revealed that U11680 is a chimeric sequence mixed with
DNA sequence from Chromosome 8, and that the sequence lacked two
long intron sequences within the putative exon 1 sequence, although
the above-mentioned promoter sequence encoding nucleotides −325
to +102 remained intact. We also found that one of the two intron
sequences which are lost in U11680 encodes a cis-acting promoter for
expression of an additional GPAT1 transcript variant. This paper reveals
the genomic organization, transcriptional activity and the differential
regulation of the two net promoter regions of the GPAT1 gene in mice.
2. Materials and methods
2.1. Bioinformatics analysis
BLAST-N searching against the mouse genome (http://www.ncbi.
nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10090) was
performed to analyze the chromosomal localization and exon/intron
organization of the previously reported mouse GPAT1 promoter
sequence (NCBI/GenBank accession number U11680) [20].
2.2. Animal experiments
Male db/db (obese) mice and db/m+ (non-obese control) mice at
6 weeks of age were purchased from Charles River Japan (Yokohama,
Japan). All animal procedures were performed in accordance with the
institutional guidelines of Tokushima University. Mice were housed at
a constant room temperature of 23±1 °C with a 12-hour light/dark
cycle, and were fed a standard non-puriﬁed diet (Oriental Yeast,
Tokyo, Japan) with food and water available ad libitum. At 8 weeks of
age, mice were randomly assigned to one of two groups: a fasted
group (48 h) or a fed group with free access to food and water.
Following the fasting (or feeding) period, body weight and food intake
were measured and blood was collected from the abdominal aorta
after surgery under anesthesia with an intraperitoneal injection of
pentobarbital (50 mg/kg). Epididymal fat depots were then collected
and weighed. Blood glucose levels were determined using a glucose
sensor (Arkley, Kyoto, Japan). Plasma insulin levels were measuredusing an insulin ELISA kit for mice (Shibayagi, Gunma, Japan). Plasma
concentrations of TAG, total cholesterol, and free fatty acid were
measured using commercial kits (Wako, Osaka, Japan). Liver lipids
were extracted by the method of Folch et al. [24] as modiﬁed by
Drackley et al. [25], and concentrations of total lipid were determined
gravimetrically after drying under a stream of nitrogen gas [25]. The
lipid extract was redissolved in isopropyl alcohol, and concentrations
of TAG were measured by a colorimetric enzymatic procedure using a
commercial kit (Wako).
2.3. Cell culture
HepG2 cells and 3T3-L1 preadipocytes were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) containing 10% fetal bovine serum
(FBS) and 0.1% gentamycin. In some experiments, the 3T3-L1 pre-
adipocytes were induced to differentiate by changing the medium to
DMEM containing 10% FBS, 10 μg/ml insulin, 0.5 mM methylisobutyl-
xanthine and 1 μM dexamethasone. After 48 h, this medium was
replaced with DMEM supplemented with 10% FBS, and cells were then
maintained in this medium for 8 days (medium was changed every
2 days) [4]. Mouse hepatocyteswere isolated frommale ddYmice (Japan
SLC, Shizuoka, Japan) aged 8–10 weeks using the collagenase perfusion
method [26], andwere thenmaintained inWilliams'mediumcontaining
1 nM insulin, 1 nM dexamethasone, 10% FBS and 0.1% gentamycin.
2.4. Isolation of total RNA and genomic DNA from mouse tissues/cells
Total RNA was extracted from mouse tissues or cultured cells with
TRIzol reagent (Invitrogen, Carlsbad, CA). RNA was further puriﬁed
using an RNeasy kit (QIAGEN, Valencia, CA) before use. Mouse
genomic DNA was isolated from the livers of C57BL/6 mice (Japan
SLC) using the PUREGENE® Genome DNA Puriﬁcation kit (Gentra
Systems, Minneapolis, MN).
2.5. 5′-Rapid ampliﬁcation of cDNA ends (RACE)
Ampliﬁcation of the 5′ end of mouse GPAT1 transcripts was
performedusing theGeneRacer™Kit (Invitrogen) on livermRNA isolated
from a C57BL/6 mouse. A GeneRacer™ RNA oligonucleotide adaptor (5′-
CGACUGGAGCACGAGGACACUGACAUGGACUGAAGGAGUAGAAA-3′)
was ligated to the 5′ end of decapped mRNA using T4 RNA ligase
(provided in the kit). First strand cDNA synthesis was then carried out
using random primers (provided in the kit). GPAT1-speciﬁc primers, 5′-
TGGATGGCTTTGGACTGCTGCTG-3′ (nucleotide position +469 to +491
relative to the translation initiation site) and 5′-ATCTGGGTTCAACT-
CCGCAGCCA-3′ (nucleotide position +437 to +459 relative to the
translation initiation site) and adaptor-speciﬁc primers (provided in
the kit) were used in the primary and secondary PCR rounds with the
Expand High FidelityPLUS PCR System (Roche Diagnostics, Tokyo, Japan).
The resulting PCR productswere cloned into the pCR®2.1-TOPO vector of
the TOPO TACloning Kit (Invitrogen) and the nucleotide sequence of the
cDNA fragments (5′ of GPAT1-V1, V2, andV3)was conﬁrmedwith anABI
PRISM 3100-Avant Genetic Analyzer (Applied Biosystems, Foster, CA)
using a BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems), following the manufacturer's protocol.
2.6. RT-PCR
Total RNA from mouse tissues or cultured cells was reverse
transcribed using the ThermoScript RT-PCR System (Invitrogen).
Gene-speciﬁc primers for each GPAT1 transcript variant and β-actin
(internal standard) (Table 1) were designed to amplify a 199-bp, 172-
bp, 196-bp and 510-bp fragment of GPAT1-V1, GPAT1-V2, GPAT1-V3
and β-actin cDNA, respectively. PCR reactions were carried out using
Taq DNA Polymerase (New England Biolabs, Inc, Beverly, MA) with the
following cycling parameters: 94 °C for 2min; 35 cycles of 94 °C for 30 s,
Table 1
Primer sets used for PCR
Target Primer sequence Localization
GPAT1-V1
(for RT-PCR, qRT-PCR)
F: 5′-CCTGGGGCTGTCTTCTTCTG-3′ Exon 1a
R: 5′-CTTTGGCTTGTGGCTTCTAGG-3′ Exon 1b
GPAT1-V2
(for RT-PCR, qRT-PCR)
F: 5′-GCTGTGTACCCGAAGGTCTC-3′ Exon 1a
R: 5′-CCAAACCATGTGTGTATCCTTG-3′ Exons 1a/1c junction
GPAT1-V3
(for RT-PCR, qRT-PCR)
F: 5′-ATTCCTTTCTCAGAGCCTGG-3′ See also Fig. 2A
R: 5′-GCAAGTCCCAAACCATGTG-3′ Exon 1c
GPAT1-total
(for qRT-PCR)
F: 5′-GGAAGGTGCTGCTATTCCTG-3′ Exon 3
R: 5′-CATCCTCTGTGCCTTGTGTG-3′ Exons 4/5 junction
SREBP-1c
(for qRT-PCR)
F: 5′-GGAGCCATGGATTGCACATT-3′
R: 5′-AGAGGAGGCCAGAGAAGCAGA-3′
USF-1
(for qRT-PCR)
F: 5′-ACGTCTTCCGAACTGAGAATGG-3′
R: 5′-GGTGAAAGCTCCCTGGATCA-3′
18S ribosomal RNA
(for qRT-PCR)
F: 5′-AAACGGCTACCACATCCAAG-3′
R: 5′-GGCCTCGAAAGAGTCCTGTA-3′
β-actin (for RT-PCR) F: 5′-GATGACGATATCGCTGCGCT-3′
R: 5′-TAGATGGGCACAGTGTGGGT-3′
F: forward primer, R: reverse primer. qRT-PCR: quantitative RT-PCR.
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7min. Ampliﬁcationof theβ-actin cDNA fragmentwas carried outwith
the same PCR system using the following cycling parameters: 94 °C for
2 min; 28 cycles of 94 °C for 30 s, 56.5 °C for 30 s, and 72 °C for 1 min;
and a ﬁnal extension at 72 °C for 7 min. The PCR products were then
electrophoresed on a 1.5% agarose gel.
2.7. Quantitative real-time RT-PCR
Total RNA isolated from the liver of db/db or db/m+ mouse or
primary cultured hepatocytes was reverse transcribed using TaKaRa
PrimeScript® RT reagent kits (TaKaRa, Kyoto, Japan). Quantitative real-
time PCR was performed with the LightCycler system (Roche
Diagnostics) using TaKaRa SYBR Premix Ex Taq (TaKaRa) and the
gene-speciﬁc primers listed in Table 1. After the reaction, each PCR
product was veriﬁed for its single ampliﬁcation by melting curve
analysis, and also by agarose gel electrophoresis of the products
followed by subcloning into a pCR®2.1-TOPO vector (Invitrogen) and
nucleotide sequencing as described above. The expression levels were
normalized to the expression of 18S ribosomal RNA (see Table 1 for
primer sequences) in each sample and are given in arbitrary units.
2.8. Plasmids
A series of 5′-ﬂanking DNA fragments encoding nucleotides −1797,
−789, −728, and −325 to +103 of the mouse GPAT1 exon 1a, and
−2107, −257, −107, −91, and −20 to +152 of the mouse GPAT1 exon 1b
(relative to the transcription start site) was generated by PCR using
C57BL/6 mouse genomic DNA and the speciﬁc primers listed in
supplementary Table S1. PCR products were subcloned with the TOPO
TA Cloning Kit (Invitrogen), and the nucleotide sequence of each DNA
fragment was conﬁrmed as described above. Each DNA insert was
isolated with restriction enzymes (supplementary Table S1), and
inserted into the same restriction sites of the pGL3-basic luciferase
reporter vector (Promega, Madison, WI), generating PGL 1a (−1797),
(−789), (−728), (−325) and PGL 1b (−2107), (−257), (−107), (−91) and
(−20). PGL 1a (−86) was constructed by digesting PGL 1a (−1797)
plasmid with Hind III, and inserting the fragment into the Hind III site
of the pGL3-basic vector. PGL 1b (−809) was generated by cutting out a
1.3-kb Sac I fragment from the PGL 1b (−2107) plasmid, followed by
self-ligating the remaining fragment at the Sac I site. PGL 1b (−458)
was constructed by cutting out a 1.65-kb fragment from the PGL 1b
(−2107) plasmid with Nhe I and Bln I (both generate a 5′-CTAG
extension), and self-ligating the remaining fragment at the 5′-CTAG
extension ends. PGL 1b (−257)m1, PGL 1b (−107)m, and PGL 1b (−91)m
were constructed by the samemethod as PGL 1b (−257), PGL 1b (−107),
and PGL 1b (−91), respectively, but using the speciﬁc mutant (sense)primers listed in supplementary Table S1. PGL 1b (−257)m2 and PGL 1b
(−257)m3 were generated by site-directed mutagenesis [27] using a
PGL 1b (−257) plasmid and the PCR primers listed in supplementary
Table S1. All plasmids were puriﬁed with a plasmid puriﬁcation kit
(QIAGEN) before use.
A mouse GPAT1 cDNA including an open reading frame (ORF) but
lacking a translational stop codon in its nucleotide sequence was
ampliﬁed by RT-PCR using the Expand High FidelityPLUS PCR System
(Roche Diagnostics) on mouse liver RNA. The gene-speciﬁc primers
used are as follows: forward: 5′-TCTGCCATGGAGGAGTCTTC-3′ (trans-
lational initiation codon ATG is underlined), reverse: 5′-CAGCACCA-
CAAAACTCAGAATATAC -3′. The PCR product was subcloned using a
TOPO TA Cloning® Kit (Invitrogen), and the nucleotide sequence of the
GPAT1 cDNA fragment was conﬁrmed as described above. A BamHI
and Not I double-digested fragment was ligated in frame into the
pcDNA3.1/Myc-His (+) vector (Invitrogen), so that the resulting fusion
construct encoded a myc epitope plus 6×His tag at the C terminus of
GPAT1 (GPAT1-myc). A pCR®2.1-TOPO vector containing a 5′ fragment
of either GPAT1-V1, V2, or V3 (obtained by the 5′-RACE method) (see
above) was subjected to PCR with speciﬁc forward primers (for
GPAT1-V1 and V2: 5′-AAGGATCCACTGTTGCAAAACCATCCTGGAC-3′,
for GPAT1-V3: 5′-AAGGATCCATTCCTTTCTCAGAGCCTGGCAA-3′)
(BamHI restriction sites are underlined) and the reverse primer [5′-
ATCTGGGTTCAACTCCGCAGCCA-3′ (nucleotide position +437 to +459
relative to the translation initiation site)]. The PCR product was
subcloned using a TOPO TA Cloning® Kit (Invitrogen). A sequence-
conﬁrmed DNA fragment was isolated by digestion with BamHI and
PshA I (nucleotide position +329 relative to the translation initiation
site) and inserted into the same restriction sites of the GPAT1-myc
plasmid, generating GPAT1-V1-myc, GPAT1-V2-myc, andGPAT1-V3-myc
expression plasmids.
A human SREBP-1c (hSREBP-1c) (a.a. 1-449) expression plasmid (in
pcDNA3.1/Myc-His (+) vector) was constructed as described previously
[28]. A human SREBP-1c (a.a. 66-449) (termed hSREBP-1-DN) was
ampliﬁed by PCR by the same method as for hSREBP-1c (1-449), but
using a different forward primer:5-TCCTGAGCATGCCGCAGGCA-3′
(designed in exon 2). Note that the ‘GG’ dinucleotides in the normal
sequence were replaced with ‘AT’ in the primer sequence to form the
translation initiation codon ATG (underlined).
A cDNA fragment of human USF-1 (hUSF-1; NCBI/GenBank
accession number NM_007122) was ampliﬁed by RT-PCR and the PCR
product was subcloned using a TOPO TA Cloning® Kit (Invitrogen). A
sequence-conﬁrmed ORF fragment with (hUSF-1) or without (hUSF-1/
BD; a dominant negative form) sequence from exon 4 [29] was isolated
by digestion with EcoR I, and inserted into the pcDNA3.1 vector
(Invitrogen).
2.9. Coupled transcription/translation
After linearization of an equal amount (1 μg) of the GPAT1-myc,
GPAT1-V1-myc, GPAT1-V2-myc, or GPAT1-V3-myc expression plasmid
or empty vector [pcDNA3.1/Myc-His(+)], each GPAT1 protein was
synthesized in vitro under the control of the T7 promoter using a TNT®
Quick Coupled Transcription/Translation System (Promega, Madison,
WI) at 30°C for 90min in the presence of 20 μMmethionine. An hUSF-1
expression plasmid (in pcDNA3.1 vector) (constructed as described
above) was also subjected to the same reaction and the generated
protein were used for an Electrophoretic Mobility Shift Assay (EMSA)
(see below).
2.10. Luciferase assay
HepG2 cells grown in a 24-well plate were transiently transfected
with 0.12 μg of the luciferase reporter plasmid, and 0.06 μg of either
hSREBP-1c (1-449), hSREBP-1-DN, hUSF-1, or hUSF-1/BD expression
plasmid using the Lipofectamine™ and Plus™ reagents (Invitrogen).
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determined by co-transfectingwith 0.06 μg of aβ-galactosidase (β-gal)
expression vector, pCMV-β (Stratagene, La Jolla, CA). After 48 h, cells
were harvested in a lysis buffer supplied with the luciferase assay
kit (Promega), and the lysates were assayed for luciferase activity
and β-gal activity as described previously [28].
2.11. Transfection of siRNA
Double-stranded RNA duplexes used for knockdown of mouse
USF-1 (sc-36784) or mouse SREBP-1 (sc-36558) were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). A control RNA duplex
with a scrambled sequence (sc-37007) was also obtained from Santa
Cruz Biotechnology, Inc. Primary cultures of mouse hepatocytes were
transfected with either of these siRNAs using the Lipofectamine 2000
reagent (Invitrogen) [26]. Cells were used 48 h after transfection.
2.12. Extraction of nuclear protein
Extraction of liver nuclear protein was performed as previously
reported [30] with somemodiﬁcations. Mouse liver was homogenized
in Buffer A [10 mM Tris–Cl, pH 7.5, 0.25 M sucrose, 3 mMMgCl2, 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 4 μg/ml leupeptin, and 4 μg/ml
aprotinin] using a Dounce homogenizer with an A-type pestle (10
strokes), followed by centrifugation at 300×g for 5 min at 2 °C. The
pellet was resuspended in Buffer A, adjusted to 1% Nonidet P-40, and
homogenized. The homogenate was then centrifuged (300×g for
5 min at 2 °C.). The nuclear pellet was resuspended in Buffer B (50 mM
Hepes, pH 7.4, 0.1 M KCl, 3 mMMgCl2, 1 mM EDTA, 10% glycerol, 1 mM
PMSF, 4 μg/ml leupeptin, and 4 μg/ml aprotinin), and adjusted to 0.4 M
ammonium sulfate. Themixturewas agitated gently at 4 °C for 40min,
and then centrifuged at 100,000×g for 60 min. The supernatant was
used as a nuclear extract.
2.13. Immunoblotting
Equal amounts of the sample proteins were denatured by boiling
for 5 min in a sodium dodecyl sulfate (SDS) sample buffer containing
1% β-mercaptoethanol. The proteins were then electrophoresed on an
SDS-polyacrylamide gel and transferred onto an Immobilon-P mem-
brane (Millipore, Bedford, MA). The membrane was blocked in 5%
skimmilk in Tris-buffered saline containing 0.05% Tween 20 for 1 hour
and incubatedwith an anti-myc tag rabbit polyclonal antibody (1: 500,
Cell Signaling Technology, Inc, MA, USA), anti-USF-1 rabbit polyclonal
antibody (1: 1000, Santa Cruz Biotechnology, Inc.), or anti-SREBP-1
rabbit polyclonal antibody (1: 1000, Santa Cruz Biotechnology, Inc.).
Proteins were then visualized with an anti-rabbit IgG horseradish
peroxidase-conjugated secondary antibody (1:10 000, Biosource
International, Camarillo, CA) using an ECL Plus detection kit
(Amersham Pharmacia Biotech, Aylesbury, UK).
2.14. EMSA
EMSA was performed as described previously [31]. Double-
stranded oligonucleotides corresponding to nucleotides −111 to −88
(oligo. A: 5′-CTTTTAGGTCACATTGCCCTGGAC-3′), or −88 to −65 (oligo.
B: 5′-CTACTCGGTCACGTGATCATCTTG-3′) in the 5′-ﬂanking region of
exon 1b (relative to the transcription start site), as well as their mutant
sequences; oligo. Am; 5′-CTTTTAGATATCATATCCTTGGAC-3′, and oligo.
Bm; 5′-CTACTCGGTTCGATGATCATCTTG-3′were synthesized (mutated
positions are underlined). Double-stranded oligonucleotides encoding
an E-box positive sequence [32] or a negative sequence (in which the
E-box sequence is disrupted) were also synthesized. Puriﬁed oligo-
nucleotides were labeled by T4 polynucleotide kinasewith [γ-32P] ATP
(N259 TBq/mmol; MP Biomedicals, Irvine, CA). The labeled probes
were further puriﬁed with MicroSpin™ G-25 Columns (GE HealthcareUK Ltd., UK) before use. The binding reaction was performed for
30 min at room temperature in a ﬁnal volume of 20 μl containing
75 mM Tris–HCl, 375 mM NaCl, 7.5 mM EDTA, 7.5 mM dithiothreitol,
37.6% glycerol, 1.5% NP–40, 5 mg/ml BSA, 0.05 mg/ml Poly (dI) Poly
(dC), 1 μl of in vitro synthesized hUSF-1 protein, and 100 nM of the
double-stranded oligonucleotide probe. For the competition assay,
unlabeled double-stranded oligonucleotide (10 μM) was added to the
binding buffer. The reactionmixturewas then electrophoresed on a 5%
polyacrylamide gel. The gel was then dried and analyzed with a bio-
imaging analyzer (BAS-1500, Fuji-ﬁlm, Tokyo).
2.15. Chromatin immunoprecipitation (ChIP)
A ChIP assay was performed as previously described [33] with
somemodiﬁcations. The liver samples from db/m+ or db/dbmice were
cross-linked with 1% formaldehyde (in PBS) at room temperature for
15 min. The reaction was terminated by the addition of 125 mM
glycine. Crosslinked liver samples were washed once with cold PBS
and swelled in RSB buffer [10 mM Tris–HCl (pH 7.4), 3 mM MgCl2,
10 mM NaCl, 2% NP–40, 1 μg/ml aprotinin, 1 μg/ml leupeptin, and
1 mM PMSF], and then homogenized with a douncer. After
centrifugation, pelleted nuclei were washed with RSB buffer and
after additional centrifugation, resuspended in nuclear lysis buffer
[50 mM Tris–HCl (pH 8.1), 1% SDS, 10 mM EDTA, 1 μg/ml aprotinin,
1 μg/ml leupeptin, and 1 mM PMSF]. The resulting chromatin solution
was then sonicated using a MICROSON™ XL2000 sonicator (MISONIX,
Farmingdale, NY) for 10×8 s to shear chromatin. Chromatin size was
determined by agarose electrophoresis to ensure that the average size
was between 200 and 400 bp. After centrifugation, the supernatant
was diluted 1:10 in dilution buffer [16.7 mM Tris–HCl (pH 8.1), 0.01%
SDS, 1.1% Triton X-100, 1.2 mM EDTA, 150 mM NaCl, and the protease
inhibitors]. The diluted sampleswere pre-clearedwith blocked protein
A-sepharose (Sigma, St. Louis, MO). Following centrifugation, the
supernatants were mixed with 2 µg of anti-USF1 antibody (sc-8983X;
Santa Cruz), 2 μg of anti-SREBP-1 antibody (sc-8984; Santa Cruz) that
recognizes both 1a and 1c isoforms, or 2 μg of non-immuno rabbit IgG
(Santa Cruz) and incubated overnight at 4 °C. Antibody–protein–DNA
complexes were isolated by immunoprecipitation with preblocked
protein A-sepharose. Following extensive washing, these complexes
were eluted with elution buffer (100mMNaHCO3,1% SDS, and 10 mM
dithiothreitol). After addition of 0.2MNaCl, sampleswere incubated at
65 °C for 4 h to reverse the formaldehyde cross-links. Aliquots of the
precleared chromatin solutions without antibody incubation (termed
“input”) were also subjected to de-crosslinking during this process.
After digestionwith RNase A (20 mg/ml, 37 °C, 30 min) and proteinase
K (50 mg/ml, 50 °C, 60 min), DNA was extracted from each sample.
Puriﬁed DNA was subjected to quantitative PCR using the following
primers: for the E-box in promoter 1a: 5′-CAAAGTAGACCCAGCCA-
GACC-3′(sense) and 5′-GGTGTCTTCTTGGCTTCGC-3′ (antisense); for the
estrogen receptor response element (ERR)-like sequence with E-box
(E4) in promoter 1b: 5′-CCCTTTAACTGGGAGAGCAGAG-3′ (sense), and
5′-TTTTGTTCAGGGTGATCTTTTGCC-3′ (antisense); and for the SRE-like
sequence in promoter 1a: 5′-CCAACTCACCCCAGTGCAG-3′ (sense) and
5′-TTGATCAGCCAATCGAAAGC-3′ (antisense). The values for non-
immuno IgG-immunoprecipitated DNA were subtracted from the
values for USF-1 or SREBP-1-immunoprecipitated DNA in each sample.
The levels of immunoprecipitated DNA were then normalized to the
levels of initial immunoprecipitable DNA (corresponding to the
amounts of PCR products in each “input” sample) and are given in
arbitrary units.
2.16. Statistical analysis
Data are expressed as the means±SD. Data were analyzed by
ANOVA plus Bonferroni multiple comparison tests. A P-valueb0.05
was considered to be statistically signiﬁcant.
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3.1. Genomic organization of the mouse GPAT1 gene
The genomic organization of the mouse GPAT1 gene was analyzed
in silico using NCBI genome search programs with the previously
reported 5′-ﬂanking DNA sequence of the GPAT1 gene (GenBank
accession number U11680) [20] as a probe. As shown in Fig. 1A,
genome analysis revealed that the DNA region upstream from −428
[relative to the transcriptional initiation site (+1)] of this sequence
(termed U11680-upper) was mapped to contigs NT_039457.6,
NW_001030892.1 and NW_000339.1, all of which were localized on
Chromosome 8. However, the DNA region downstream from −428
(termed U11680-lower) was mapped to contigs of Chromosome 19
(NT_039687.6, NW_001030648.1 and NW_000148.1) (Fig. 1A and B). A
GATC sequence was located at the U11680-upper–lower sequence
junction (Fig. 1A).An NCBI genome analysis (BLAST Mouse Sequences;
http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?
taxid=10090) of the U11680-lower sequence further revealed that the
DNA region downstream from +1 must be divided into three putative
exon sequences (termed exons 1a, 1b, and 1c). Exons 1a and 1b are
located approximately 28 kb and 5 kb, respectively, upstream of exon
1c in the mouse genome (Fig. 1B). An NCBI genome analysis also
revealed that all sequences at the exon–intron junctions are consistent
with the AG–GT rule (Table 2) [34].
3.2. The mouse GPAT1 gene produces three transcript variants
Previously, Jerkins et al. identiﬁed a transcription initiation site of
the GPAT1 gene by primer extension analysis using a primer that was
complementary to nucleotides +99 to +115 (relative to the transcrip-
tion start site) [20]. Thus, this primer was located in exon 1a according
to our analysis (Fig. 1B). Here we carried out 5′-RACE analysis to obtain
the sequence of the 5′-end of the GPAT1 transcript using GPAT1-
speciﬁc reverse primers in exon 5. As shown in Fig. 2A, three transcript
variants were obtained and were designated GPAT1 transcript variant
1 (GPAT1-V1), variant 2 (GPAT1-V2), and variant 3 (GPAT1-V3). GPAT1-
V1 cDNA contained all three exon 1 sequences (1a,1b and 1c), whereas
GPAT1-V2 lacked the exon 1b sequence (Fig. 2A). The transcriptionFig.1.Net genomic organization of themouseGPAT1gene. (A) Structure of the promoter region
et al. (NCBI/GenBank accession number U11680) [20]. Genome analysis revealed that the DNA
U11680-upper)wasmapped to contigs of Chromosome (Ch.) 8 (NT_039457.6, NW_001030892.
Ch. 19 (NT_039687.6, NW_001030648.1 or NW_000148.1). The border (GATC sequence) betwe
that the DNA region downstream from +1 must be divided into three exon sequences (exons
mouse GPAT1 gene on Ch. 19. Boxes indicate the exons. The numbers of nucleotides in each e
upstreamof exon 1b in theGPAT1-V3 variant (see Fig. 2A). The locations of promoters 1a and 1b
are also shown in panel B. The locations of the translation initiation codon (ATG) in exon 1c ainitiation site (+1) of GPAT1-V1 and V2 corresponded to the site that
was shown in the previous report by Jerkins et al. [20] (see also Fig.
1B). GPAT1-V3 lacked exon 1a, and the transcription initiation site (+1)
of this variant was located at the 13th upstream nucleotide of exon 1b
in the mouse genome (Figs. 1B and 2A).
3.3. Expression of GPAT1 variants in mouse tissues and cultured cells
The expression patterns of each GPAT1 variant (GPAT1-V1, V2 and
V3) were examined by RT-PCR analysis using speciﬁc primers
(indicated in Table 1 and Fig. 2A) and RNA from various mouse tissues
and cultured cells. As shown in Fig. 2B, all three variants were
expressed in all tissues and cultured cells tested.
3.4. Translational efﬁciency of each GPAT1 variant
As shown in Fig. 2A, the protein-coding region of all GPAT1 mRNA
variants begins at exon 1c, suggesting that an identical protein is
produced from each of the three transcript variants. However, changes
in the 5′-untranslated region of the mRNA might affect translational
efﬁciency of the transcript as has been shown for other genes [35]. To
examine the synthetic efﬁciency of proteins from each GPAT1 mRNA
variant, in vitro protein production [35] was assessed for each variant.
As shown in Fig. 2C, a coupled transcription/translation system
yielded similar amounts of each GPAT1 protein variant. These levels
were, however, lower compared to those produced from a GPAT1
cDNA without exons 1a and 1b (GPAT1 ORF alone; GPAT1-myc) (Fig.
2C), suggesting a role of exons 1a and 1b in attenuating GPAT1 protein
production.
3.5. Identiﬁcation of GPAT1 gene promoters
We have been unable to generate a full length DNA sequence of
U11680 [20] from the mouse genome by PCR. However, 5′-ﬂanking
DNA fragments encoding nucleotides −1797 to +103 of the GPAT1-
V1 (and V2) (promoter 1a; NCBI/GenBank accession number
AB372190), and −2107 to +152 of the GPAT1-V3 (promoter 1b;
NCBI/GenBank accession number AB372191) were generated by PCR
based on the genome sequence information in NCBI/GenBank (Fig.with putative exon1 of themouseGPAT1 gene according to theprevious report by Jerkins
region upstream from −428 [relative to the transcriptional initiation site (+1)] (termed
1 orNW_000339.1),whereas a downstreamsequence (U11680-lower)matched contigs of
en the U11680-upper and -lower sequences is shown. Genome analysis further revealed
1a, 1b, and 1c in panel B). (B) Net promoter regions and exon/intron organization of the
xon or intron are shown. The diagonal box in panel B indicates a 5′-additional sequence
for expression of the three GPAT1 transcript variants (GPAT1-V1, V2, andV3) (see Fig. 2A)
re indicated in both panels.
Table 2
Nucleotide sequences at the exon–intron junctions of the mouse GPAT1 gene (from exons 1a to 1c)
Exon number Splice acceptor Splice donor
1a – ACATCAAGGATACAGgtatttgagcaactggga
1b ttgtttcattcctttctcagAGCCTGGCAAAAGAT ATTAAACAGGAGTTGAgtaagtataccggact
1c tagtgcttatttcttacagCACATGGTTTGGGACT –
Exon and intron nucleotide sequences are shown in upper-case and lower-case letters, respectively. Donor and acceptor splice sites are underlined.
44 M. Yoshida et al. / Biochimica et Biophysica Acta 1791 (2009) 39–521B, supplementary Fig. S1 and S2). Various 5′-segments for promoter
1a (from −1797, −789, −728, −325, and −86 to +103) and promoter 1b
(from −2107, −809, −458, and −91 to +152) ﬂanking each transcrip-Fig. 2. The GPAT1 gene produces three transcript variants in mice. (A) Structures of the GPAT1
the exons. The transcription initiation sites (+1) and the translational initiation codon (ATG)
well as for the quantitative real-time RT-PCR analysis (Fig. 9). Primer sequences are shown i
GPAT1-V3 variant (see also Fig. 1B). (B) Expression of GPAT1 transcript variants in mouse tissu
skeletal muscle (gastrocnemius). WAT: white adipose tissue (epididymal). BAT: brown a
adipocytes. 3T3-L1 (post): differentiated 3T3-L1 adipocytes. (C) Immunoblotting of the in v
transcript variant cDNA (V1: GPAT1-V1-myc, V2: GPAT1-V2-myc, and V3: GPAT1-V3-myc). E:
as an ORF alone control for the GPAT1 cDNA (o). Five microliters of the TNT® product (see
Immunoblotting was performed using an anti-myc tag rabbit polyclonal antibody. Similar rtional start site were inserted into a luciferase reporter plasmid, and
transcriptional activities of these DNA regions were evaluated using
HepG2 cells. As shown in Fig. 3, basal promoter activity was regulatedtranscript variants (GPAT1-V1, V2 and V3) obtained by 5′-RACE analysis. Boxes indicate
are indicated. Arrows indicate the locations of the primers used for RT-PCR (panel B) as
n Table 1. The diagonal box indicates 5′-additional sequence upstream of exon 1b in the
es (C57BL/6 mice) and cultured cells. β-actinwas used as an internal control. Sk. muscle:
dipose tissue. Hepatocytes: primary cultured hepatocytes. 3T3-L1 (pre): 3T3-L1 pre-
itro-translated myc-tagged proteins generated from the plasmids carrying each GPAT1
empty vector. The plasmid that carries GPAT1 cDNA but lacks exons 1a and 1b was used
Materials and methods section) was electrophoresed on an SDS-polyacrylamide gel.
esults were obtained from two independent experiments.
Fig. 3. Transcriptional activities of promoter 1a (A) and promoter 1b (B) of the mouse GPAT1 gene. Transcriptional activities of promoter 1a (A) and promoter 1b (B) of the mouse
GPAT1 gene. HepG2 cells were transfected with one of the luciferase reporter plasmids [for promoter 1a: PGL 1a (−1797), (−789), (−728), (−325) or (−86), for promoter 1b: PGL 1b
(−2107), (−809), (−458), or (−91)] and luciferase activities were evaluated at 48 h post-transfection. The location of the nucleotides of GATC at −428 (relative to the transcriptional
start site in promoter 1a) is shown by a dotted line (see also Fig.1). Luciferase activity was normalized for β-gal activity. A pGL3-basic vector (PGL) was used as a promoter-less control.
Data are expressed as the means±SD of four culture wells (in a 24-well plate) in each group. The mean value for the promoter-less control (PGL) is designated as 1. ⁎Pb0.05 vs. PGL. L:
luciferase. Similar results were obtained from three independent experiments.
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and between −91 and +152 for promoter 1b (Fig. 3B). Additional DNA
regionsmight act asmodest enhancers (e.g. between −325 and −86 for
promoter 1a) or silencers (e.g. between −728 and −325 for promoter
1a) for GPAT1 gene transcription (Fig. 3A and B).Fig. 4. Regulation of GPAT1 promoter activity by USF-1 and SREBP-1. (A) Regulation of promot
SREBP-1c. (C) Regulation of promoters 1a and 1b activity by SREBP-1-DN. HepG2 cells were tr
(−325), or (−86), for promoter 1b: PGL 1b (−2107)] together with an hUSF-1, hSREBP-1c or h
evaluated at 48 h post-transfection. A pGL3-basic vector (PGL) was used as a promoter-less con
The location of the nucleotides of GATC at −428 (relative to the transcription start site in promo
E1 to E4 in panel B, and the same boxes in panel C) are shown by closed boxes. The locations of
promoter 1a are indicated byopenboxes. Luciferase activitywasnormalized forβ-gal activity. D
Themean value for a promoter-less control (PGL) with an empty vector (pcDNA3.1) is designat
from two independent experiments.3.6. Regulation of GPAT1 promoter activity by USF-1 and SREBP-1
Promoter 1a of the mouse GPAT1 gene contained an E-box (−324)
and SRE-like sequences (SRE1: −186, SRE2: −170, and SRE3: −64
relative to the transcription start site) within the DNA region fromer 1a activity by USF-1 and SREBP-1c. (B) Regulation of promoter 1b activity by USF-1 and
ansfected with one of the luciferase reporter plasmids [for promoter 1a: PGL 1a (−1797),
SREBP-1-DN -encoding or a non-coding (pcDNA3.1) plasmid. Luciferase activities were
trol. Plasmids encoding hUSF-1 and hSREBP-1cwere co-transfected in some cell cultures.
ter 1a) is shown bya dotted line (see also Fig.1). The locations of E-boxes (E in panel A and
the SRE-like sequences (SRE1 to SRE3 in panel A and the same boxes in panel C) [21,23] in
ata are expressed as themeans±SDof four culturewells (in a 24-well plate) in eachgroup.
ed as 1. ⁎Pb0.05 vs. empty vector (pcDNA3.1). L: luciferase. Similar results were obtained
Fig. 5. Regulation of GPAT1 promoter 1b activity by hUSF-1 (A) and hUSF-1/BD (B). HepG2 cells were transfected with one of the luciferase reporter plasmids (as indicated) together
with an hUSF-1 or an hUSF-1/BD-encoding or a non-coding (pcDNA3.1) plasmid. Luciferase activities were evaluated at 48 h post-transfection. A pGL3-basic vector (PGL) was used as
a promoter-less control. The locations of four E-boxes (E1 to E4) are shown by closed boxes. Luciferase activity was normalized for β-gal activity. Data are expressed as the means±SD
of four culturewells (in a 24-well plate) in each group. Themean value for a promoter-less control (PGL) with an empty vector (pcDNA3.1) is designated as 1. ⁎Pb0.05 vs. empty vector
(pcDNA3.1). L: luciferase. Similar results were obtained from two independent experiments.
Fig. 6. Effect of site-directed mutagenesis in PGL 1b reporter plasmids on hUSF-1 (A) and hUSF-1/BD (B)-stimulated promoter 1b activity. HepG2 cells were transfected with one of the
luciferase reporter plasmids (as indicated) together with an hUSF-1 or an hUSF-1/BD-encoding or a non-coding (pcDNA3.1) plasmid. Luciferase activities were evaluated at 48 h post-
transfection.ApGL3-basic vector (PGL)wasusedas apromoter-less control. The locationsof fourE-boxes (E1 toE4) are shownbygrayboxes. ERR-like sequence (A-107GGTCACATTGCCCT-93)
located upstream of E4 is shown by open boxes. Site-directedmutagenesis resulted in the disruption of eachmotif (indicated by anX). Luciferase activity was normalized for β-gal activity.
Data are expressed as themeans±SDof fourculturewells (in a 24-well plate) in eachgroup. Themeanvalue for a promoter-less control (PGL)with anempty vector (pcDNA3.1) is designated
as 1. ⁎Pb0.05 vs. empty vector (pcDNA3.1). L: luciferase. Similar results were obtained from two independent experiments.
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additional SRE (-like) sequences [36,37] were found in the promoter
region upstream of −428 in promoter 1a. In the present study, hSREBP-
1c, but not hUSF-1, activated the transcriptional activity of PGL 1a
(−325) in HepG2 cells (Fig. 4A), as had been shown in a previous
report using Drosophila SL2 cells [23]. Similar results were also
observed for PGL 1a (−1797) which contained an additional
upstream promoter sequence from −428 (Fig. 4A). A previous
study [23] demonstrated that USF-1 and SREBP-1 synergistically
activate the GPAT1 promoter (1a in our categorization). As shown in
Fig. 4A, a similar cooperative activation of promoter 1a by hUSF-1
and hSREBP-1c was observed for PGL 1a (−325), but it was much less
for PGL 1a (−86) that lacked an E-box (−324). The synergistic
activation was not observed with PGL 1a (−1797) (Fig. 4A),
suggesting that there may be some negative regulatory effects of
an undetermined DNA region upstream from −428. In the down-
stream promoter 1b, four E-box-like sequences [E1 (CACATG): −251
to −246, E2 (CAGCTG): −203 to −198, E3 (CAGCTG): −123 to −118,
and E4 (CACGTG): −80 to −75 relative to the transcriptional start
site] (consensus sequence CANNTG) [29,38] were identiﬁed (Fig. 4B
and supplementary Fig. S2). No SRE-like sequence was found in
promoter 1b (up to −2107 bp). As shown in Fig. 4B, hUSF-1, but not
hSREBP-1c, enhanced the luciferase activity of PGL 1b (−2107). Co-
expression of hSREBP-1c with hUSF-1 did not further increase hUSF-
1-activated luciferase activity in PGL 1b (−2107)-transfected cells
(Fig. 4B). It has been demonstrated that SREBP-1a proteins without
the N-terminal 1-90 (1-66 in 1c-isoform) amino acids (termed
SREBP-1-DN) serves as a dominant negative regulator of SREBP-1-
dependent gene expression [39]. As shown in Fig. 4C, the luciferase
activity of PGL 1a (−1797)-transfected cells was largely attenuated
(Pb0.05) by overexpression of hSREBP-1-DN. In contrast, over-
expression of SREBP-1-DN had little effect on the luciferase activityFig. 7. Binding of USF-1 to ERR-like and E4 sequences in promoter 1b of the GPAT1 gene. (A) T
for Electrophoretic Mobility Shift Assay (EMSA). ERR-like sequence (A−107GGTCACATTGCCCT
indicated. Mutated positions in oligo. Am and Bm are underlined. The nucleotide sequences
Each labeled oligonucleotide probe was mixed with an in vitro-synthesized hUSF-1 protein
Materials and methods section. The reaction mixture was then electrophoresed on a 5% pol
sequence. Similar results were obtained from two independent experiments.of cells expressing PGL 1b (−2107) constructs (Fig. 4C). Thus, these
two promoters of the mouse GPAT1 gene appear to be differentially
regulated by USF-1 and SREBP-1.
3.7. hUSF-1 activates and hUSF-1/BD attenuates promoter 1b activity of
the GPAT1 gene
The response of the promoter to exogenous hUSF-1 overexpression
was examined using various 5′-segments of promoter 1b in HepG2
cells. As shown in Fig. 5A, cells transfected with PGL 1b (−2107),
(−809), (−458), (−257), and (−107) signiﬁcantly increased their
luciferase activity in response to hUSF-1 overexpression, whereas
cells transfected with PGL 1b (−91) showed an attenuated increase in
luciferase activity. The hUSF-1-stimulated luciferase activity of the
cells with PGL 1b (−20) was slightly higher than that of the cells
transfected with PGL vector alone (Fig. 5A). As shown in Fig. 5B,
overexpression of hUSF-1/BD, a dominant negative regulator of hUSF-
1-dependent gene expression [29], signiﬁcantly attenuated the basal
luciferase activity of PGL 1b (−2107), (−809), (−458), (−257), and
(−107). In contrast, the luciferase activity of PGL 1b (−91) appeared to
be unchanged by hUSF-1/BD overexpression (Fig. 5B). These results
suggest that the nucleotide sequence between −107 and −91 contains
a region responsive to USF-1. It should be noted that hUSF-1/BD
increased the luciferase activity of PGL 1b (−20) (Fig. 5B). It has been
reported that both normal and BD–USF proteins can transactivate
promoter activity through certain speciﬁc sequences such as an
initiator (Inr) element in the core promoter [40]. The consensus
sequence of Inr is Py-Py-A (+1)-N-T/A-Py-Py [41], which is con-
served in the core promoter region of promoter 1b [TCA(+1)TTCC]
(supplementary Fig. S2). However, point mutations of the Inr
sequence [e.g. TCATAAA; underlined mutations can diminish USF-
1-stimulated transcription of the adenovirus major late (Ad-ML)he nucleotide sequences of the oligonucleotide (oligo.) probes (also used as competitors)
−93) is double-underlined. An E4 sequence (the forth E-box in the promoter 1b) is also
for E-box positive (posi.) [32] and negative (nega.) sequences are also shown. (B) EMSA.
in the presence or absence of unlabeled oligonucleotides (competitors) as described in
yacrylamide gel. A; oligo. A, B; oligo. B, Am; oligo. Am, Bm; oligo. Bm, P; E-box positive
Fig. 8. Effect of RNAi against USF-1 or SREBP-1 on GPAT1 expression levels in mouse
hepatocytes. Hepatocytes were transfected with siRNAs that target mouse USF-1 or
mouse SREBP-1, or with control siRNA (scrambled sequence) 48 h prior to RNA
extraction. (A) Endogenous mRNA expression levels of USF-1 and SREBP-1a/1c in
siRNA-transfected mouse hepatocytes (quantitative real-time RT-PCR analysis). (B)
Endogenous mRNA expression levels of each GPAT1 transcript variant [GPAT1-V1 (V1),
V2 (V2), and V3 (V3)] in siRNA-transfected mouse hepatocytes (quantitative real-time
RT-PCR analysis). Data are expressed as the means±SD of 5–6 culture dishes (6 cm
dishes) in each group. Each mRNA expression level was normalized for the expression
of 18S ribosomal RNA in each group. The mean value for the control siRNA group is
designated as 1. ⁎Pb0.05, when compared with control siRNA group.
Table 3
Physical and biochemical characteristics of db/m+ and db/db mice (8 weeks of age)
db/m+ db/db
Fed Fasted (48 h) Fed Fasted (48 h)
Body weight (g) 26.6±0.4 20.5±0.7⁎ 40.4±1.8† 36.3±1.2⁎⁎
Food intake
[g/12 h (light)]
0.26±0.05 – 1.64±0.16† –
[g/12 h (dark)] 2.26±0.09 – 4.10±0.53# –
[g/24 h] 2.53±0.04 – 5.74±0.69# –
Epididymal fat (g) 0.36±0.07 0.18±0.03⁎ 1.53±0.07† 1.54±0.10
Liver total lipid
(µg/mg tissue)
38.5±6.0 176.6±99.1⁎⁎ 70.6±21.5# 150.0±22.9⁎
Liver TAG (µg/mg tissue) 4.8±2.0 30.6±3.7⁎ 18.0±2.9† 26.0±9.4
Blood glucose (mg/100 ml) 127.5±9.2 34.7±2.1⁎ 432.7±48† 70.5±14.1⁎
Plasma insulin (ng/ml) 1.58±0.38 0.69±0.32⁎⁎ 5.40±1.13† 1.51±0.56⁎
Plasma TAG (mg/100 ml) 115.9±9.3 72.5±22.2⁎⁎ 373.9±24.7† 64.7±8.4⁎
Plasma total cholesterol
(mg/100 ml)
60.5±2.5 70.9±16.1 118.4±20.4† 78.8±4.9⁎⁎
Plasma free fatty acid
(mEq/l)
0.10±0.03 0.78±0.28⁎ 0.90±0.26† 0.94±0.29
⁎Pb0.01,
⁎⁎Pb0.05, when compared with fed group.
†Pb0.01,
#Pb0.05, when compared with db/m+ group.
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exogenous hUSF-1/BD or hUSF-1 proteins in the present study (data
not shown). Thus, we ﬁnd no evidence of a weak USF-1-responsive
domain in the core region of promoter 1b (located between −20 and
+152). In this regard, if PGL 1b (−91) does not contain another USF-1-
responsive sequence, hUSF-1/BD should increase its promoter activity.
However, as shown in Fig. 5B, hUSF-1/BD actually failed to increase the
luciferase activity of PGL 1b (−91). Thus, it is plausible that a
nucleotide sequence located between −91 and −20 also responds to
the dominant-negative effect of hUSF-1/BD. We hypothesize here that
there is also a USF-1 responsive element located between −91 and−20. Our results additionally suggest that the three E-box-like
sequences (E1 to E3) within the DNA region from −257 to −107 play
no functional role in USF-1-mediated activation of promoter 1b. Point
mutations in each E-box (E1 to E3) indeed did not signiﬁcantly affect
exogenous hUSF-1- or hUSF-1/BD-induced changes in promoter 1b
activity (Fig. 6A and B).
3.8. Identiﬁcation of the USF-1-responsive sequence in promoter 1b
We hypothesized that at least two USF-1-responsive sequences are
located in promoter 1b (between −107 and −91 and between −91 and
−20 relative to the transcription start site; see above). The nucleotide
sequence positioned from −107 to −93 of promoter 1bwas found to be
an estrogen receptor response element (ERR; consensus sequence
AGGTCAnnnTGACCT)-like sequence, A−107GGTCACATTGCCCT−93 (Fig.
6A, B and supplementary Fig. S2), which could be recognized by USF
proteins [43]. ERR (-like) sequences are known to be regulated by
estrogens; however, a preliminary study failed to show an effect of β-
estradiol (10−9 to 10−7 M) administration on promoter 1b activity in
HepG2 cells (data not shown). This sequence also contained a non-
canonical E-box sequence of C−103ACATTG−97 (CANNNTG). In addition,
the nucleotide sequence from −80 to −75 (CACGTG) corresponded to
E4, a fourth E-box sequence in promoter 1b (Fig. 6A and B). As shown
in Fig. 6A and B, the basal promoter activity of PGL 1b (−107) and PGL
1b (−91) was decreased by disruption of ERR-like [PGL 1b (−107)m]
and E4 [PGL 1b (−91)m] sequences, respectively. The hUSF-1-
stimulated increase in luciferase activity was also less in PGL 1b
(−107)m or PGL 1b (−91)m-transfected cells compared to PGL 1b
(−107) or PGL 1b (−91) -transfected cells, respectively (Fig. 6A). In
addition, exogenous overexpression of hUSF-1/BD failed to attenuate
the luciferase activity of PGL 1b (−107)m-transfected HepG2 cells as
was seen in the cells that were transfected with PGL 1b (−91) plasmid
(Fig. 6B). In PGL 1b (−91)m-transfected cells, exogenous overexpres-
sion of hUSF-1/BD slightly increased luciferase activity as was seen in
the PGL 1b (−20)-transfected cells (Fig. 6B). Thus, ERR-like and E4
sequences in the promoter 1b of the GPAT1 gene can serve as targets
for USF-1 action.
3.9. USF-1 binds to ERR-like and E4 sequences in the promoter 1b
To examine whether the USF-1 protein actually binds to the two
USF-1-response elements (ERR-like and E4 sequence) in promoter 1b,
EMSA was performed using in vitro translated hUSF-1 protein and
49M. Yoshida et al. / Biochimica et Biophysica Acta 1791 (2009) 39–52speciﬁc oligonucleotide probes or competitors shown in Fig. 7A. As
shown in Fig. 7B, the formation of complexes between hUSF-1 and
oligonucleotides carrying ERR-like sequence (oligo. A) or E4 sequence
(oligo. B) was observed. The mutant probes Am and Bm failed to form
complexes with hUSF-1 protein (Fig. 7B). The formation of a complex
of hUSF-1 and oligo. A (or B) was inhibited in the presence of a non-
labeled competitor A (or B) or an E-box positive sequence, but not in
the presence of a non-labeled competitor Am (or Bm) (Fig. 7B). These
results suggest that the USF-1 protein binds speciﬁcally to ERR-like
sequence (−107 to −93) and E4 sequence (−80 to −75) located in
promoter 1b of the GPAT1 gene.
3.10. Effect of RNAi against USF-1 or SREBP-1 on GPAT1 expression levels
in mouse hepatocytes
As shown above (Fig. 4), USF-1 can activate promoters 1a and 1b,
whereas SREBP-1 only activates promoter 1a of theGPAT1 gene. Hence,Fig. 9. Effect of fasting/feeding or obesity on the expression levels of GPAT1 in mouse liver.
and db/db mice fed or fasted for 48 h (quantitative real-time RT-PCR analysis). (B) mRNA e
fed or fasted for 48 h (quantitative real-time RT-PCR analysis). (C) Intranuclear protein le
(Immunoblotting). Representative data from two mice in each group are shown. (D) Binding
in the liver of db/m+ and db/db mice fed or fasted for 48 h (ChIP assay). Intranuclear DNA–p
amount of the precipitated DNA was quantiﬁed with quantitative real-time PCR analysis as
means±SD of four mice in each group. Each mRNA expression level was normalized for th
group is designated as 1. ⁎Pb0.05, when compared with the fed group.the effects of a gene knockdown of endogenous USF-1 or SREBP-1 on
themRNA levels of the GPAT1 transcript variants (V1, V2, and V3)were
examined in primary cultured mouse hepatocytes using speciﬁc
siRNAs for each transcription factor. As shown in Fig. 8A, transfection
of the cells with siRNA for USF-1 and SREBP-1 signiﬁcantly decreased
mRNA levels of endogenous USF-1 and SREBP-1 (both the 1a and 1c
isoforms), respectively, when compared to cells transfected with non-
speciﬁc control siRNAs. In this study, the mRNA levels of each GPAT1
transcript variant were measured (Fig. 8B). An siRNA for USF-1
signiﬁcantly decreased mRNA levels of all three GPAT1 variants.
However, knockdown of the endogenous SREBP-1 by siRNA signiﬁ-
cantly decreased mRNA levels of GPAT1-V1 and V2, but not of the V3
variant. The change in the mRNA levels of total GPAT1 was similar to
that of the GPAT1-V1 or V2 levels (Fig. 8B). These results suggest that
basal expression levels of USF-1 are necessary for expression of all
three GPAT1 variants, i.e., it is necessary for the activity of both
promoters in mouse hepatocytes. However, endogenous SREBP-1(A) mRNA expression levels of each GPAT1 variant or total GPAT1 in the liver of db/m+
xpression levels of USF-1, SREBP-1a, or SREBP-1c in the liver of db/m+ and db/db mice
vels of USF-1 or SREBP-1 in the liver of db/m+ and db/db mice fed or fasted for 48 h
levels of USF-1 or SREBP-1 proteins to promoter 1a or promoter 1b of the GPAT1 gene
rotein complexes were immunoprecipitated (IP) with the antibodies indicated and the
described in Materials and methods section. Data in A, B, and D are expressed as the
e expression of 18S ribosomal RNA in each group. The mean value for the fed db/m+
50 M. Yoshida et al. / Biochimica et Biophysica Acta 1791 (2009) 39–52regulates mRNA levels of GPAT1-V1 and V2 variants, i.e., it regulates
only promoter 1a in these cells.
3.11. Involvement of USF-1 and SREBP-1 in nutritional regulation of
GPAT1 gene expression in vivo
The expression levels of each GPAT1 gene variant and their
relationships with the expression levels or promoter binding status of
USF-1 and SREBP-1 were analyzed in the liver of obese db/db and non-
obese db/m+ (control) mice after fasting (48 h) or under ad lib feeding
in this study. As shown in Table 3, db/db mice exhibited hyperphagia,
hyperinsulinemia, and hyperglycemia as well as hyperlipidemia and
attained a higher body weight as well as greater visceral fat mass
compared to the normal db/m+ mice. The amounts of total lipids and
TAG in the liver were also higher in db/db mice than in normal
controls (Table 3). Fasting of the animals in both groups decreased
blood concentrations of glucose, insulin and TAG while also resulting
in lipid accumulation in the liver (Table 3).
As shown in Fig. 9A, feeding increased GPAT1-V1 and V2 as well as
total GPAT1mRNA levels both in the control and db/dbmice. GPAT1-V3
mRNA levels, however, did not respond to fasting/feedingmanipulation
in these mice (Fig. 9A). The obese and diabetic condition of the db/db
mice had little effect on the expression levels of all GPAT1 variants
tested (Fig. 9A). mRNA expression levels and intranuclear protein levels
of USF-1 were not increased by feeding, whereas those of SREBP-1(1a
and 1c) were signiﬁcantly up-regulated by feeding in both mouse
genotypes (Fig. 9B and C). To examine the binding levels of USF-1 and
SREBP-1 proteins to GPAT1 promoters, ChIP was performed using liver
nuclear fractions isolated from the fasted and fedmice. As shown in Fig.
9D, the binding of USF-1 to promoter 1a or 1b of the GPAT1 gene was
not affected by fasting/feeding manipulation or the obese and diabetic
condition of the db/db mice. However, the binding of SREBP-1 to
promoter 1a in the liver was increased slightly by feeding in both
genotypes, although the hyperphagia seen in db/dbmice did not further
potentiate this binding (Fig. 9D).Fig. 10. Summarized model showing the regulation of hepatic GPAT1 gene expression in v
promoter 1a and promoter 1b on Chromosome (Ch.) 19. Boxes indicate the exons. The trans
Feeding facilitates intranuclear accumulation of SREBP-1 which in turn binds to SRE-like s
transcription of V1 (G-V1) and V2 (G-V2) variants of the GPAT1 gene. USF-1 can associate wi
expression levels as well as the binding levels of USF-1 to both promoters are not altered
GPAT1-V3 variant (G-V3) remain unclear.4. Discussion
Here we have shown that three transcript variants (GPAT1-V1, V2,
and V3) of the GPAT1 gene are expressed in the mouse. The
transcription of both GPAT1-V1 and V2 mRNA is facilitated by the
promoter 1a while the GPAT1-V3 variant is regulated by the down-
stream promoter 1b. Studies with experimental animals in vivo have
suggested that the mRNA expression levels of the GPAT1-V1 and V2
variants were regulated by fasting and feeding whereas GPAT1-V3
mRNA levels were unchanged by nutritional manipulation (Fig. 9). The
obese and diabetic condition of the db/db mice had little effect on the
expression levels of all three GPAT1 variants (Fig. 9). The feeding-
stimulated increases in the mRNA levels of total GPAT1 (V1+V2+V3)
were similar to those of the V1 and V2 isoforms (Fig. 9), suggesting
that promoter 1a activity is much greater than promoter 1b activity.
The luciferase activity of transfected cells expressing promoter 1a
sequence in the PGL3 vector (approximately 20 to 150 times higher
than pGL3 vector alone) was indeed greater than that of the cells
expressing promoter 1b sequence (approximately 5 to 20 times higher
than pGL3 vector alone) in this study (Fig. 3). Thus, previously
observed changes in the mRNA levels of GPAT1 under fasting/feeding
manipulation [3] would appear to reﬂect changes in the expression
levels of the V1 and V2 variants, but not of the V3 variant of this gene.
Our in vitro studies led us to conclude that USF-1 regulates the
transcriptional activity of both promoter 1a and promoter 1b of the
GPAT1 gene. However, mRNA expression levels, nuclear protein levels,
and promoter (1a and 1b)-binding levels of USF-1 in our mouse livers
were not increased by routine feeding in vivo (Fig. 9). Thus, USF-1
might not be involved in the feeding-induced stimulation of GPAT1
gene expression, although the basal promoter binding of the USF-1
protein is essential for the transcription of lipogenic genes including
GPAT1 [23] (see also Fig. 8). On the other hand, mRNA expression
levels and nuclear protein levels of SREBP-1 in mouse liver were
signiﬁcantly higher under fed conditions than fasting conditions (Fig.
9) as had been demonstrated in previous studies [44]. The feeding-ivo. Transcription of the mouse GPAT1 gene is controlled by at least two promoters:
cription initiation sites (+1) and the translational initiation codon (ATG) are indicated.
equences on promoter 1a of the GPAT1 gene. Activation of promoter 1a increases the
th E-boxes (on promoter 1a or 1b) or ERR-like sequence (on promoter 1b); however, the
by fasting/feeding in vivo. Pathophysiological stimuli that regulate the transcription of
51M. Yoshida et al. / Biochimica et Biophysica Acta 1791 (2009) 39–52induced rise in the binding levels of SREBP-1 to promoter 1a of the
GPAT1gene (Fig. 9)was almost identical to theprevious results ofGrifﬁn
et al. [23]. In the present study, exogenous overexpression of SREBP-1c
stimulated, whereas overexpression of SREBP-1-DN inhibited, the
activity of promoter 1a but not of promoter 1b in HepG2 cells (Fig. 4).
An RNAi-induced knockdown of endogenous SREBP-1 actually
decreased expression of GPAT1-V1 and V2, but not of GPAT1-V3
mRNA levels in mouse hepatocytes (Fig. 8). Thus, SREBP-1 could play a
signiﬁcant role in feeding-induced activationofpromoter 1a, facilitating
GPAT1gene expression in the liver (Fig.10). In contrast, the downstream
promoter 1b which lacks SRE (-like) sequence would not respond to
fasting or feeding in vivo (Fig. 10).
The molecular stimuli that facilitate SREBP-1-dependent GPAT1
transcription remain unclear. Several previous studies have suggested
that insulin may be a critical factor mediating the postprandial
increase in lipogenic gene expression [3,38,45,46]. Hepatic GPAT1
gene expression has been reported to be increased following an
insulin injection in animals, while it is decreased in streptozotocin
(STZ)-induced type I diabetic liver [3]. Thus, the observed rise in the
plasma insulin levels under fed conditions (Table 3) might reﬂect an
involvement of insulin in the feeding-stimulated rise in hepatic GPAT1
mRNA levels. However, we have previously demonstrated that feeding
itself even in non-diabetic mice is not sufﬁcient to activate down-
stream signaling molecules (e.g. Akt/protein kinase B and glycogen
synthase kinase-3α/β) of insulin action in the liver [26]. Although we
and others have shown a slight induction of SREBP-1 mRNA
expression by a supra-physiological concentration of insulin
(100 nM) in vitro [28,47], our preliminary experiments revealed that
the insulin at this concentration was not sufﬁcient to induce GPAT1
gene expression in primary mouse hepatocytes (M. Yoshida and N.
Harada, unpublished data). A recent study of transgenic mice
expressing a transgene with an SREBP-1c promoter-driven reporter
clearly demonstrated an insulin-independent refeeding response of
SREBP-1 gene transcription in vivo [48]. Thus, changes in insulin levels
during routine feeding in mice may not be sufﬁcient to elevate GPAT1
gene expression in the liver. An alternative hypothesis is the
possibility that glucose could stimulate GPAT1 gene expression.
Recently, the liver X receptors (LXRs) have been identiﬁed as novel
glucose sensors in mammalian cells [49], although another study
failed to show this effect [50]. SREBP-1c expression is known to be one
of the targets of LXR action [50] and it was indeed slightly elevated in
liver cells in a high glucose environment [28,51]. Given the fact that
feeding of LXRα/β knockout mice failed to increase GPAT1 gene
expression in the liver [50], a hyperglycemic effect on the feeding-
stimulated increase of hepatic GPAT1 gene expressionwas speculated.
However, hepatic GPAT1 mRNA levels were not increased even in the
presence of hyperglycemia in our db/dbmice (Fig. 9 and Table 3) or in
STZ-induced type I diabetic mice [3]. A high glucose environment
(25 mM) indeed failed to potentiate GPAT1 promoter 1a or 1b activity
in our preliminary luciferase assays (data not shown). Thus, the
involvement of a high glucose environment in the regulation of GPAT1
gene expression in the liver remains to be clariﬁed. Further
investigation is needed to elucidate the molecular mechanisms
required for up-regulation of hepatic GPAT1 gene expression during
routine feeding.
It should be noted here that fasting caused the accumulation of
lipids, including triacylglycerol, in the liver (Table 3). The increase in
intrahepatic lipids during fasting has been described to be mainly due
to an increased inﬂux of free fatty acids into the liver [52]. Lee et al.
[53] has demonstrated using a knockout mouse that peroxisome
proliferator-activated receptor-α (PPAR-α), a well known transcrip-
tion factor which mediates transcription of lipolytic genes [54], plays
an important role in maintaining hepatic lipid proﬁles during fasting.
In the upstream region of promoter 1a of the GPAT1 gene, i.e., in the
sequence upstream of −428 in promoter 1a, a PPAR-responsive
element (consensus AGGTCAnAGGTCA)-like sequence 5′-AGGTCA-CAGGGCA-3′ at the nucleotide position −747 to −735 (relative to the
transcriptional start site) was found (supplementary Fig. S1). In this
motif, the hexamers AGGTCA were arranged as direct repeats with an
interspacing of 1 bp [termed direct repeat 1 (DR1)] [55]. A
heterodimer of PPARα and retinoid X receptor (RXR) binds to this
motif and regulates target gene expression [55]. However, when ‘C’ is
an intervening base in a DR1, the binding intensity of the PPARα/RXRα
heterodimer to DR1 largely decreases [55]. The DR1-like sequence
identiﬁed in promoter 1a of the GPAT1 gene has ‘C’ as an intervening
base between two AGGTCA-like hexamers. Thus, our preliminary
luciferase assays in HepG2 cells did not show a response of this motif
to either exogenous overexpression of PPARα/RXRα or to the selective
PPARα ligand Wy-14643 (up to 100 μM) (data not shown).
Recently, Aneja et al. have identiﬁed two promoters of the rat
GPAT1 gene [56]. One promoter (they termed this the “distal
promoter”) matches the mouse promoter 1a, while the other (termed
the “proximal promoter”) does not match mouse promoter 1b, but is
located downstream of the second exon (which corresponds to exon
1c in mouse) of the rat GPAT1 gene [56]. Nutritional regulation of
hepatic GPAT1 expression in both the mouse and the rat was mainly
controlled by the activity of promoter 1a [the distal promoter in the rat
[56]]. Future studies should be undertaken to identify the stimuli that
target the remaining promoters in mammalian cells. Elucidation of
alternative regulatory systems for promoter selectivity of GPAT1 gene
would help to understand the molecular basis of glycerophospholipid
synthesis in various pathophysiological conditions.
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